Novo Nordisk, food and drug administration

Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
Novo’s Weight Loss Drugs Removed from FDA Shortage List
The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list. The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and diabetes drugs,
Novo Nordisk Shares Rise After FDA Clears Shortage of Anti-Obesity Drugs
Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o
Novo Nordisk up 6%, Hims & Hers down 15% as FDA says Ozempic shortage over
Shares of Novo Nordisk (NVO) are up 6% in pre-market trading after a FDA drug shortage notice indicated that a shortage of several versions of
Ozempic and Wegovy shortage ends, setting up weight loss drug showdown
Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared Friday. Why it matters: That's good news for Novo Nordisk (whose stock rose 5% Friday) and potentially bad news for Hims & Hers (which fell 26%).
FDA announces end to Wegovy and Ozempic drug shortages, but it could mean higher prices
The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is over.
Novo Nordisk A/S (NVO): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the ...
Lilly, Novo dominance to continue as TD Cowen lifts 2030 GLP-1 sales forecast by 38%
Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...
FiercePharma2d
Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Eli Lilly Bets Big on Weight-Loss Pill With $550 Million Inventory Stockpile
(Reuters) - Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage ...
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...
Eli Lilly (LLY) Stockpiles Weight Loss Pill Ahead of Regulatory Approval
Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...
2 Important Insights From Novo Nordisk's Earnings Call
Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.